Board of directors (11)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (14)
Company facts
- Chair
- —
- In S&P 500 since
- Mar 1957
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC industry
- Pharmaceutical Preparations
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Julia A. Haller Director | Sale | 3,800 | $63.31 | $241K |
| Sep 9, 2026 | Cristian Massacesi EVP, Chief Med Offr, Head of Dev | Sale | 6,249 | $64.57 | $403K |
| Aug 25, 2026 | Phil M. Holzer SVP and Controller | Sale | 500 | $67.50 | $34K |
| Apr 1, 2026 | David Elkins V EVP, Chief Financial Officer | Sale | 25,519 | $61.60 | $1.6M |
| Apr 1, 2026 | David Elkins V EVP, Chief Financial Officer | Sale | 4,481 | $62.05 | $278K |
| Sep 2, 2025 | David Elkins V EVP, Chief Financial Officer | Sale | 56,000 | $47.33 | $2.7M |
| Aug 2, 2025 | Bartie Wendy Short EVP, Corporate Affairs | Sale | 378 | $44.23 | $17K |
| May 9, 2025 | Benjamin Hickey President, RayzeBio Org. | Sale | 97 | $38.01 | $4K |
| Apr 25, 2025 | Samit Hirawat EVP, Chief Med.Offr., Drug Dev. | Buy | 4,250 | $47.58 | $202K |
| Feb 20, 2025 | Christopher S. Boerner Chief Executive Officer | Buy | 2,000 | $55.05 | $110K |
| Feb 14, 2025 | Samit Hirawat EVP, Chief Med.Offr., Drug Dev. | Buy | 1,823 | $54.84 | $100K |
| Nov 4, 2024 | Phil M. Holzer SVP and Controller | Sale | 700 | $55.62 | $39K |
| Nov 1, 2024 | Samit Hirawat EVP, Chief Med.Offr., Drug Dev. | Buy | 1,830 | $54.68 | $100K |
| Dec 5, 2023 | Christopher S. Boerner Chief Executive Officer | Buy | 2,000 | $49.78 | $100K |
| Nov 28, 2023 | Christopher S. Boerner Chief Executive Officer | Buy | 3,071 | $48.86 | $150K |
| Nov 20, 2023 | Theodore R. Samuels II Director | Buy | 8,500 | $49.81 | $423K |
| Aug 24, 2023 | Ann Powell EVP, Chief Human Resources | Sale | 17,986 | $61.25 | $1.1M |
| Aug 3, 2023 | Robert M. Plenge EVP, Chief Research Officer | Sale | 732 | $61.14 | $45K |
| May 3, 2023 | Rupert Vessey EVP & President, Research | Sale | 50,385 | $67.06 | $3.4M |
| Feb 6, 2023 | Giovanni Caforio Executive Chair of the Board | Sale | 240,000 | $74.65 | $17.9M |
| Feb 6, 2023 | Ann Powell EVP, Chief Human Resources | Sale | 11,183 | $74.69 | $835K |
| Nov 9, 2022 | Ann Powell EVP, Chief Human Resources | Sale | 16,250 | $80.45 | $1.3M |
| Nov 7, 2022 | Rupert Vessey EVP & President, Research | Sale | 45,910 | $78.88 | $3.6M |
| Sep 20, 2022 | Giovanni Caforio Executive Chair of the Board | Sale | 25,000 | $69.71 | $1.7M |
| Sep 15, 2022 | Giovanni Caforio Executive Chair of the Board | Sale | 50,000 | $71.84 | $3.6M |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Jul 25, 2025
(b) On July 25, 2025, Bristol-Myers Squibb Company (the “Company”) announced that Dr. Samit Hirawat, Chief Medical Officer and Head of Development, will leave the Company by November 1, 2025. In connection with his departure, Dr. Hirawat will transition from his current role as Executive Vice President, Chief Medical Officer and Head of Development, effective August 1, 2025, to become an advisor to the Company. (e) In connection with his departure, Dr. Hirawat will be entitled to (i) severance benefits in accordance with the Company’s U.S.
Read the 8-K filing - Feb 18, 2025
(b) On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025. Ms. Leung is expected to remain with the Company for a transition period until her successor’s appointment in order to assist with the transition of her duties. (e) In connection with her retirement, Ms. Leung will be entitled to retirement benefits in accordance with the Company’s existing compensation plans.
Read the 8-K filing - Jun 18, 2024
(d) On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024. The size of the Board was increased to eleven, effective July 1, 2024, in connection with the election of Mr. McMullen. Mr. McMullen is 63 years old and has more than 20 years of executive experience and leadership skills managing large businesses and global operations as well as a proven track record of delivering excellent shareholder returns. During his tenure as CEO, Mr. McMullen led Agilent Technologies, Inc.’s (“Agilent”) transformation into a market leading life-sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability. Mr.
Read the 8-K filing - Mar 18, 2024
(b) On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders. The Board also set the number of directors at ten, effective immediately after the 2024 Annual Meeting of Shareholders, which is expected to be held on May 7, 2024.
Read the 8-K filing - Feb 15, 2024
Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024. Mr. Holzer, 48, joined the Company in 2001. Most recently, from 2021 to 2024, he served as Senior Vice President, Finance, Treasury and Tax Operations. Prior to that, he served in multiple roles of increasing responsibility, including Senior Vice President, Enterprise Integrations from 2019 to 2021, Vice President and Head of Finance, Research & Development from 2018 to 2019, Chief Audit Officer from 2015 to 2018, and Vice President, U.S. Commercialization Finance from 2013 to 2015. Mr. Holzer has a Bachelor of Science degree in Accounting from The University of Tampa and is a Certified Public Accountant. Mr.
Read the 8-K filing - Oct 31, 2023
(b)(c) On April 26, 2023, Bristol Myers Squibb Company (the “Company”) filed a Form 8-K to announce the retirement of Giovanni Caforio, M.D. as Chief Executive Officer and his election as Executive Chairman of the Board of Directors of the Company (the “Board”), effective November 1, 2023, and the appointment of Christopher Boerner, Ph.D. as Chief Executive Officer by the Board, effective November 1, 2023. Theodore R. Samuels continues to serve as Lead Independent Director. On October 25, 2023, Dr. Caforio advised the Board that he will not stand for re-election to the Board at the 2024 Annual Meeting of Shareholders, and will retire from the Board, effective April 1, 2024. The size of the Board will be set at eleven, effective April 1, 2024, in connection with the retirement of Dr. Caforio. On October 25, 2023, the Board approved Dr.
Read the 8-K filing - May 4, 2023
(d) On April 26, 2023, Bristol Myers Squibb Company (the “Company”) announced that the Board of Directors of the Company (“Board”) appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023. On May 2, 2023, the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023, after the Annual Meeting. The size of the Board was increased to twelve, effective May 2, 2023, in connection with the election of Dr. Boerner. Dr. Boerner, 52, has worked for the Company since 2015 in roles of increasing seniority. He served as the Company’s Executive Vice President and Chief Commercialization Officer from August 2018 to April 2023. Dr. Boerner previously served as Head, International Markets from October 2017 to July 2018, and as President and Head of U.S.
Read the 8-K filing - Apr 26, 2023
(b)(c) O n April 26, 2023, Bristol Myers Squibb Company (the “Company”) announced that Giovanni Caforio, M.D., the Company’s Chairman of the Board of Directors (“Board”) and Chief Executive Officer, has decided to retire as Chief Executive Officer (“CEO”) effective November 1, 2023. Dr. Caforio will continue to serve as Chairman of the Board until he retires as CEO on November 1, 2023, and after that will serve as Executive Chairman of the Board for a transition period to be determined by the Board. Theodore R. Samuels will continue to serve as Lead Independent Director. In addition, on April 21, 2023, the Board appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023. The Board also intends to appoint Dr. Boerner to the Board after the Annual Meeting. Dr.
Read the 8-K filing - Jan 31, 2023
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (b) Effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President, Research and Early Development, has decided to leave Bristol-Myers Squibb Company (the “Company”). (e) In connection with his departure, Dr. Vessey will be entitled to (i) severance benefits in accordance with the Company’s Senior Executive Severance Plan, and (ii) (A) pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs) and (B) full vesting of his 2019 Restricted Stock Units Inducement Award, in each case, in accordance with the Company’s equity award agreements under the Company’s 2012 and 2021 Stock Award and Incentive Plans. In addition, Dr. Vessey will receive a pro-rated annual incentive payout for 2023 in the amount of $550,855.
Read the 8-K filing - Jun 15, 2022
(d) On June 14, 2022, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Deepak L. Bhatt , M.D., M.P.H., to serve as a member of the Board, effective June 14, 2022. The size of the Board was increased to eleven, effective June 14, 2022, in connection with the election of Dr. Bhatt. Mr. Deepak L. Bhatt , M.D., M.P.H., is 54 years old and has more than 20 years of experience in acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has served as the principal or co-principal investigator for cardiovascular clinical trials focused on interventional cardiology, anti-thrombotic therapy, lipid-lowering therapy, heart failure, obesity, and diabetes, among other areas. Since 2013, Dr.
Read the 8-K filing - Mar 17, 2022
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022. Ms. Greenlees , 50, most recently, from July 2021, served as Vice President and Controller, R&D Finance and Operations at AbbVie Inc. and prior to that, she served in multiple roles of increasing responsibility, including Head of Supply Chain Finance from 2020 to 2021, Head of Pricing, U.S. Commercial from 2018 to 2020, Vice President of Investor Relations from 2016 to 2018 and Vice President and Assistant Corporate Controller from 2012 to 2016. Ms. Greenless has a B.S. in Accounting and is a Certified Public Accountant. Ms.
Read the 8-K filing - Aug 9, 2021
(b) On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc . Also, effective August 3, 2021, the Board set the number of directors at ten.
Read the 8-K filing - May 20, 2021
(d) On May 14, 2021, the Board of Directors of Bristol-Myers Squibb Company (the “Company”) elected Mr. Manuel Hidalgo Medina, M.D., to serve as a member of the Board of Directors, effective June 1, 2021. The size of the Board of Directors was increased to eleven, effective June 1, 2021, in connection with the election of Dr. Hidalgo. Mr. Manuel Hidalgo Medina, M.D. is 53 years old and has more than 20 years of experience in translational and clinical research in anticancer drug development with a particular emphasis in gastrointestinal cancers. He has also led the early clinical development of new anticancer agents for pancreatic cancer among other solid tumor cancers.
Read the 8-K filing - May 4, 2021
(e) O n May 4, 2021, the stockholders of Bristol-Myers Squibb Company (the “Company”) approved the 2021 Stock Award and Incentive Plan (the “Plan”) at the annual meeting of stockholders (the “Annual Meeting”). The material terms of the Plan are summarized on pages 83 through 91 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 25, 2021 (the “Proxy Statement”), which description is incorporated by reference herein. This description of the Plan is qualified in its entirety by reference to the actual terms of the Plan, which are set forth in Exhibit B to the Proxy Statement.
Read the 8-K filing - Mar 4, 2021
(b) On March 1, 2021, Mr. Dinesh Paliwal notified Bristol-Myers Squibb Company that he will not stand for re-election to the Board of Directors at the 2021 Annual Meeting of Shareholders . The Board also set the number of directors at ten effective as of the 2021 Annual Meeting of Shareholders, which is expected to be held on May 4, 2021.
Read the 8-K filing
Show 24 older changes
- Feb 10, 2021
(b) On February 10, 2021, each of Dr. Vicki Sato, Mr. Robert Bertolini and Mr. Matthew Emmens notified Bristol-Myers Squibb Company that they will not stand for re-election to the Board of Directors at the 2021 Annual Meeting of Shareholders . The Board also set the number of directors at eleven, effective as of the 2021 Annual Meeting of Shareholders, which is expected to be held on May 4, 2021.
Read the 8-K filing - Jul 30, 2020
(d) On July 29 , 2020, the Board of Directors of Bristol-Myers Squibb Company (the “Company”) elected Ms. Paula A. Price and Mr. Derica W. Rice, to serve as members of the Board of Directors, effective September 1, 2020. The size of the Board of Directors was increased to fourteen, effective September 1, 2020, in connection with the election of these new Directors. Ms. Paula A. Price is 58 years old and has more than 30 years of financial and operational experience. Most recently, she served as Executive Vice President (EVP) and Chief Financial Officer (CFO) of Macy's, Inc. until May 2020. She currently remains an advisor to the renowned retailer. Prior to that, she was a full-time Senior Lecturer for Harvard Business School in the Accounting and Management Unit from 2014 - 2018. Before that, Ms.
Read the 8-K filing - Mar 12, 2020
(b) On March 10, 2020, Charles A. Bancroft notified Bristol-Myers Squibb Company (the “Company”) that he will retire from his position as Executive Vice President, Head of Integration and Strategy & Business Development effective March 16, 2020 .
Read the 8-K filing - Feb 24, 2020
(b) On February 20, 2020, Mr. Michael Grobstein and Mr. Alan Lacy notified Bristol-Myers Squibb Company that they will not stand for re-election to the Board of Directors at the 2020 Annual Meeting of Shareholders. The Board also set the number of directors at twelve effective as of the 2020 Annual Meeting of Shareholders , which is expected to be held on May 5, 2020 .
Read the 8-K filing - Dec 11, 2019
(d) On December 5, 2019, the Board of Directors of Bristol-Myers Squibb Company appointed Michael Bonney to the Audit Committee and the Integration Committee, Dr. Julia A. Haller to the Science & Technology Committee and Phyllis Yale to the Committee on Directors and Corporate Governance. As previously reported on the Current Report on Form 8-K filed on September 12, 2019, Michael Bonney, Dr. Julia A. Haller and Phyllis Yale were elected to serve as members of the Board of Directors, effective November 20, 2019. The size of the Board of Directors was increased to fourteen, effective November 20, 2019, in connection with the election of these new Directors.
Read the 8-K filing - Nov 20, 2019
In connection with the completion of the Merger, and effective upon the Merger Effective Time, the Compensation and Management Development Committee of the Board of Directors of BMS approved the adoption and amendment and restatement of the Celgene Corporation 2017 Stock Incentive Plan (the “Legacy 2017 Plan”) and the Celgene Corporation 2014 Equity Incentive Plan (F/K/A Juno Therapeutics, Inc.
Read the 8-K filing - Sep 12, 2019
(d) On September 11, 2019, the Board of Directors of Bristol-Myers Squibb Company (the “Company”) elected Michael Bonney, Dr. Julia A. Haller and Phyllis Yale, to serve as members of the Board of Directors, effective at the closing of the transaction with Celgene Corporation (the “Closing”). The size of the Board of Directors was increased to fourteen, effective at the Closing, in connection with the election of these new Directors. Mr. Bonney is 61 years old and currently serves as the Executive Chair of the Board of Kaleido Biosciences, Inc., having served as Chief Executive Officer and Chairman from June 2017 to August 2018. From January to July 2016, he was a Partner of Third Rock Ventures, LLC. Previously, Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (which was acquired by Merck & Co., Inc.
Read the 8-K filing - Jun 5, 2019
(b) (c) On June 5, 2019, Bristol-Myers Squibb Company (the “Company”) announced the future leadership team of the combined company effective upon completion (the “Closing”) of the Company’s pending merger with Celgene Corporation (“Celgene”). Among the changes announced are the following appointment and departure of certain officers: (1) Thomas J. Lynch, Jr., M.D., Executive Vice President and Chief Scientific Officer, will leave the company by October 1, 2019. (2) Charles A. Bancroft, Chief Financial Officer and Executive Vice President, Global Business Operations, will transition from his current position to Executive Lead for Integration effective as of the Closing. (3) David V. Elkins is appointed Executive Vice President and Chief Financial Officer effective as of the Closing. Mr.
Read the 8-K filing - Mar 8, 2019
The information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated by reference herein. Item 9 .01. Financial Statements and Exhibits. (d) Exhibits This Current Report on Form 8-K is being filed to file as exhibits the following new form of award agreements approved by the Compensation and Management Development Committee of the Board of Directors of Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) under Bristol-Myers Squibb’s 2012 Stock Award and Incentive Plan, in connection with the regular annual compensation cycle of Bristol-Myers Squibb: Exhibit No.
Read the 8-K filing - Sep 14, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Aug 28, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jul 23, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Mar 1, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jan 25, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Sep 13, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jul 14, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - May 5, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Mar 23, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Mar 8, 2017
(b)(c) On March 8, 2017, Bristol-Myers Squibb Company (the “Company”) announced the appointment and departure of certain officers and directors as follows: · Thomas J. Lynch, Jr., M.D., will resign from the Board of Directors effective March 15, 2017 and will be appointed as Executive Vice President and Chief Scientific Officer effective March 16, 2017. The size of the Board will be set at thirteen directors for the period between March 15, 2017 and May 2, 2017. As previously announced, at the 2017 annual meeting of stockholders, eleven directors will stand for election and the size of the Board will return to eleven directors. · Francis Cuss, Executive Vice President and Chief Scientific Officer, will retire from the Company after a three-month transition period. Dr.
Read the 8-K filing - Feb 21, 2017
On February 21, 2017, the board of directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) temporarily increased the size of the Board from eleven directors to fourteen directors until the 2017 annual meeting of stockholders and appointed Messrs. Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels as members of the Board to fill the newly created directorships, effective immediately. Each of Messrs. Bertolini, Emmens and Samuels will serve as directors until the 2017 annual meeting of stockholders and until his successor is duly elected and qualified. At the 2017 annual meeting of stockholders, eleven directors will stand for election, including Messrs. Bertolini, Emmens and Samuels, and the size of the Board will return to eleven directors. The Board has affirmatively determined that each of Messrs.
Read the 8-K filing - Dec 21, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jun 20, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Mar 8, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Feb 16, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing
Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | 14.6% | $3.46 | $90.0B |
| FY2024 | $48.3B | -$8.9B | -18.5% | $-4.41 | $92.6B |
| FY2023 | $45.0B | $8.0B | 17.8% | $3.86 | $95.2B |
| FY2022 | $46.2B | $6.3B | 13.7% | $2.95 | $96.8B |
| FY2021 | $46.4B | $7.0B | 15.1% | $3.12 | $109.3B |
| FY2020 | $42.5B | -$9.0B | -21.2% | $-3.99 | $118.5B |
| FY2019 | $26.1B | $3.4B | 13.2% | $2.01 | $129.3B |
| FY2018 | $22.6B | $4.9B | 21.8% | $3.01 | $34.8B |
Former directors and officers (37)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.